Metastasis to the bone in breast cancer patients is common, but metastasis specifically to the appendicular skeleton is rare. A limited number of cases in the literature describe metastatic breast cancer to the distal limbs, also known as acrometastasis. Acrometastasis in a patient with breast cancer should prompt evaluation for diffuse metastatic disease. We describe the case of a patient with recurrent triple-negative metastatic breast cancer who presented with thumb pain and swelling. Radiograph of the hand demonstrated focal soft tissue swelling over the first distal phalanx with erosive changes to the bone. Palliative radiation to the thumb resulted in symptom improvement. However, the patient succumbed to widespread metastatic disease. At autopsy, the thumb lesion was confirmed as metastatic breast adenocarcinoma. Metastatic breast carcinoma to the distal appendicular skeleton, specifically to the first digit, is a rare presentation of bony metastasis and can be an indication of late, widespread disease.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262941 | PMC |
http://dx.doi.org/10.31486/toj.22.0105 | DOI Listing |
Alzheimers Dement
December 2024
B.S.A. College of Engineering and Technology, Mathura, Uttar Pradesh, India.
Background: Cognitive dysfunction emerges as a manifestation of reduced estrogen levels following ovariectomy in an individual. However, the conventional use of estrogen replacement therapy could increase the risk of breast cancer and thromboembolism. Icariin is a natural compound that has been reported to be a neuroprotective agent against dementia.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
The TT & WF Chao Center for BRAIN and Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX, USA.
Background: Global epidemiological studies involving over nine million participants have shown a 35% lower incidence of Alzheimer's Disease (AD) in older cancer survivors compared to those without a history of cancer. This inverse relationship, consistent across recent studies with methodological controls, suggests that cancer itself, rather than cancer treatments, may offer protective factors against AD. This insight opens avenues for novel therapeutic strategies targeting early AD by harnessing cancer-associated protective factors.
View Article and Find Full Text PDFBioconjug Chem
January 2025
School of Chemistry, Raymond and Beverly Sackler Faculty of Exact Sciences, Tel-Aviv University, Tel Aviv 69978, Israel.
ENPP-1 is a transmembrane enzyme involved in nucleotide metabolism, and its overexpression is associated with various cancers, making it a potential therapeutic target and biomarker for early tumor diagnosis. Current detection methods for ENPP-1 utilize a colorimetric probe, , which has significant limitations in sensitivity. Here, we present probe , the first nucleic acid-based chemiluminescent probe designed for rapid and highly sensitive detection of ENPP-1 activity.
View Article and Find Full Text PDFANZ J Surg
December 2024
Northern Sydney Cancer Centre, Royal North Shore Hospital, University of Sydney, Sydney, New South Wales, Australia.
Curr Pharm Des
January 2025
Department of Pharmacy, Delhi Pharmaceutical Sciences and Research University, New Delhi, India.
Background: The metal oxide nanoparticles possess unique properties such as biological compatibility, superior reactivity, and capacity to develop reactive oxygen species, due to this they have drawn significant interest in cancer treatment. The various MONPs such as cerium oxide, Copper oxide, Iron oxide, Titanium dioxide, and Zinc oxide have been investigated for several types of cancers including brain, breast, cervical, colon, leukemia, liver, lung, melanoma, ovarian, and prostate cancers. However, traditional physiochemical synthetic methods for MONPs commonly include toxic materials, a major concern that raises questions regarding their biocompatibility and safety.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!